Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study

Viviana Bazan, Loredana Bruno, Giuseppe Cicero, Gaetana Di Fede, Maria Rosaria Valerio, Vito Rodolico, Antonio Russo, Mario Latteri, Valentina Agnese, Nello Grassi, Vincenza Morello, Antonino Agrusa, Rosa Maria Tomasino, Valentina Calo', Eugenio Fiorentino, Fiorentino, Grassi, Eugenio Fiorentino, Colucci, LatteriAltavilla, Mario A. Latteri, Adele Crosta, Claudia Augello, Donatella Calcara, Federica Latteri

Risultato della ricerca: Article

4 Citazioni (Scopus)

Abstract

BACKGROUND: Methylation of the p16 promoter is one of the most frequent mechanisms of gene inactivation; its incidence is extremely variable according to the type of tumor involved. Our purpose was to analyze the hypermethylation of the p16 promoter in laryngeal squamous cell carcinomas (LSCC), salivary gland (SG) tumors and in colorectal cancer (CRC), to detect any possible association with the clinicopathological features and to determine the prognostic significance of the p16 gene in the tumors analyzed.PATIENTS AND METHODS: The hypermethylation of the p16 promoter was prospectively analyzed, by MSP, in a consecutive series of 64 locally advanced LSCC patients, in a consecutive series of 33 SG tumor patients and in a consecutive series of 66 sporadic CRC patients.RESULTS: Hypermethylation was observed in 9% of the LSCC cases, in all cases of SG cancer and in 21% of the CRC cases. No significant association was observed between p16 hypermethylation and clinicopathological variables in all the tissue samples analyzed. Moreover at univariate analysis p16 mutations were not independently related at disease relapse and death in LSCC and CRC.CONCLUSIONS: The results of this study suggest that the lack of p16 function could happen in advanced stage of SG tumors.
Lingua originaleEnglish
pagine (da-a)137-141
Numero di pagine5
RivistaAnnals of Oncology
Volume17
Stato di pubblicazionePublished - 2006

Fingerprint

Glandular and Epithelial Neoplasms
Squamous Cell Carcinoma
Colorectal Neoplasms
Neck
Head
Prospective Studies
Genes
Salivary Gland Neoplasms
p16 Genes
Squamous Cell Neoplasms
Laryngeal Neoplasms
Gene Silencing
Methylation
Neoplasms
Recurrence
Mutation
Incidence

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cita questo

@article{6e51070299cf4e71820d6e2956197706,
title = "Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study",
abstract = "BACKGROUND: Methylation of the p16 promoter is one of the most frequent mechanisms of gene inactivation; its incidence is extremely variable according to the type of tumor involved. Our purpose was to analyze the hypermethylation of the p16 promoter in laryngeal squamous cell carcinomas (LSCC), salivary gland (SG) tumors and in colorectal cancer (CRC), to detect any possible association with the clinicopathological features and to determine the prognostic significance of the p16 gene in the tumors analyzed.PATIENTS AND METHODS: The hypermethylation of the p16 promoter was prospectively analyzed, by MSP, in a consecutive series of 64 locally advanced LSCC patients, in a consecutive series of 33 SG tumor patients and in a consecutive series of 66 sporadic CRC patients.RESULTS: Hypermethylation was observed in 9{\%} of the LSCC cases, in all cases of SG cancer and in 21{\%} of the CRC cases. No significant association was observed between p16 hypermethylation and clinicopathological variables in all the tissue samples analyzed. Moreover at univariate analysis p16 mutations were not independently related at disease relapse and death in LSCC and CRC.CONCLUSIONS: The results of this study suggest that the lack of p16 function could happen in advanced stage of SG tumors.",
author = "Viviana Bazan and Loredana Bruno and Giuseppe Cicero and {Di Fede}, Gaetana and Valerio, {Maria Rosaria} and Vito Rodolico and Antonio Russo and Mario Latteri and Valentina Agnese and Nello Grassi and Vincenza Morello and Antonino Agrusa and Tomasino, {Rosa Maria} and Valentina Calo' and Eugenio Fiorentino and Fiorentino and Grassi and Eugenio Fiorentino and Colucci and Latteri and Altavilla and Latteri, {Mario A.} and Adele Crosta and Claudia Augello and Donatella Calcara and Federica Latteri",
year = "2006",
language = "English",
volume = "17",
pages = "137--141",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study

AU - Bazan, Viviana

AU - Bruno, Loredana

AU - Cicero, Giuseppe

AU - Di Fede, Gaetana

AU - Valerio, Maria Rosaria

AU - Rodolico, Vito

AU - Russo, Antonio

AU - Latteri, Mario

AU - Agnese, Valentina

AU - Grassi, Nello

AU - Morello, Vincenza

AU - Agrusa, Antonino

AU - Tomasino, Rosa Maria

AU - Calo', Valentina

AU - Fiorentino, Eugenio

AU - Fiorentino, null

AU - Grassi, null

AU - Fiorentino, Eugenio

AU - Colucci, null

AU - Latteri, null

AU - Altavilla, null

AU - Latteri, Mario A.

AU - Crosta, Adele

AU - Augello, Claudia

AU - Calcara, Donatella

AU - Latteri, Federica

PY - 2006

Y1 - 2006

N2 - BACKGROUND: Methylation of the p16 promoter is one of the most frequent mechanisms of gene inactivation; its incidence is extremely variable according to the type of tumor involved. Our purpose was to analyze the hypermethylation of the p16 promoter in laryngeal squamous cell carcinomas (LSCC), salivary gland (SG) tumors and in colorectal cancer (CRC), to detect any possible association with the clinicopathological features and to determine the prognostic significance of the p16 gene in the tumors analyzed.PATIENTS AND METHODS: The hypermethylation of the p16 promoter was prospectively analyzed, by MSP, in a consecutive series of 64 locally advanced LSCC patients, in a consecutive series of 33 SG tumor patients and in a consecutive series of 66 sporadic CRC patients.RESULTS: Hypermethylation was observed in 9% of the LSCC cases, in all cases of SG cancer and in 21% of the CRC cases. No significant association was observed between p16 hypermethylation and clinicopathological variables in all the tissue samples analyzed. Moreover at univariate analysis p16 mutations were not independently related at disease relapse and death in LSCC and CRC.CONCLUSIONS: The results of this study suggest that the lack of p16 function could happen in advanced stage of SG tumors.

AB - BACKGROUND: Methylation of the p16 promoter is one of the most frequent mechanisms of gene inactivation; its incidence is extremely variable according to the type of tumor involved. Our purpose was to analyze the hypermethylation of the p16 promoter in laryngeal squamous cell carcinomas (LSCC), salivary gland (SG) tumors and in colorectal cancer (CRC), to detect any possible association with the clinicopathological features and to determine the prognostic significance of the p16 gene in the tumors analyzed.PATIENTS AND METHODS: The hypermethylation of the p16 promoter was prospectively analyzed, by MSP, in a consecutive series of 64 locally advanced LSCC patients, in a consecutive series of 33 SG tumor patients and in a consecutive series of 66 sporadic CRC patients.RESULTS: Hypermethylation was observed in 9% of the LSCC cases, in all cases of SG cancer and in 21% of the CRC cases. No significant association was observed between p16 hypermethylation and clinicopathological variables in all the tissue samples analyzed. Moreover at univariate analysis p16 mutations were not independently related at disease relapse and death in LSCC and CRC.CONCLUSIONS: The results of this study suggest that the lack of p16 function could happen in advanced stage of SG tumors.

UR - http://hdl.handle.net/10447/25963

M3 - Article

VL - 17

SP - 137

EP - 141

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -